Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients
Status:
Completed
Trial end date:
2017-02-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare icotinib with induction and maintenance chemotherapy
in the first-line treatment of advanced non-small cell lung cancer (NSCLC) patients with EGFR
mutation.